Abstract
Drug-eluting stents confer no additional late cardiovascular risk in patients with stenting of large coronary arteries when compared with bare-metal stents according to the results of the 24-month Basel Stent Cost-effectiveness Trial-PROspective Evaluation Examination [BASKET-PROVE; ISRCTN72444640].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
